FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|87|3|148-158

ISSN： 0030-2414

Source： Oncology, Vol.87, Iss.3, 2014-07, pp. : 148-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-05 ,pp. : 363-367

Karger

Access to resources Recommend Favorite

Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer

By  

Oncology, Vol. 89, Iss. 3, 2015-05 ,pp. : 152-158

Karger

Access to resources Recommend Favorite

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 118-128

Karger

Access to resources Recommend Favorite

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 187-196

Karger

Access to resources Recommend Favorite

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

By  

Oncology, Vol. 83, Iss. 3, 2012-08 ,pp. : 151-157

Karger

Access to resources Recommend Favorite